JAK3
Tyrosine-protein kinase JAK3
As of the edition of 20 October 2026, JAK3 (tyrosine-protein kinase JAK3, UniProt P52333) has 12 drugs tested at it and 14 companies on the list, 5 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P52333
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 43
- Disease areas
- Skin and connective tissue; Immune system; Bones, joints and muscles; Digestive system; Inherited and neonatal; Cancer; Blood and lymph; Lungs and airways
- Registered trials of its drugs
- 472
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 5 |
| Went quiet | 3 |
| Stopped | 3 |
| Status not established | 1 |
| Total | 12 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Tofacitinib | Marketed | Phase 4 | Ends 2028 |
| Upadacitinib | Marketed | Phase 4 | Ends 2036 |
| Ritlecitinib | Marketed | Phase 3 | Ends 2041 |
| Peficitinib | Marketed | Phase 3 | none listed |
| Delgocitinib | Marketed | Phase 3 | Ends 2031 |
| Gusacitinib | Stopped | Phase 2 | none listed |
| Izencitinib | Stopped | Phase 3 | none listed |
| Decernotinib | Went quiet | Phase 3 | none listed |
| Cerdulatinib | Stopped | Phase 3 | none listed |
| Nezulcitinib | Status not established | Phase 2 | none listed |
| AT-9283 | Went quiet | Phase 2 | none listed |
| Lepzacitinib | Went quiet | Phase 2 | none listed |
12 of 12 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 5 |
| Route B | 2 |
| Engaged | 1 |
| Undetermined | 6 |
| Total on the list | 14 |
| Company | Route |
|---|---|
| AbbVie | Route B |
| LEO Pharma | Route B |
| Otsuka | Route A |
The other 11 companies at JAK3
In the product14 companies in all; 11 are not named here, and no score is.
See the 14 companies at JAK3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.